Text Size

Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) (SAHA-I)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by University of Heidelberg.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Merck
Information provided by:
University of Heidelberg
ClinicalTrials.gov Identifier:
NCT00918489
First received: June 10, 2009
Last updated: February 14, 2011
Last verified: June 2009
History of Changes
  Purpose

Primary objective of the study is to investigate the efficacy of vorinostat in patients suffering from selected histological types of soft tissue sarcoma. Further evaluations relate to the safety and tolerability of vorinostat, its pharmacokinetics (course of plasma concentration over time) and pharmacodynamics (mode of action). Only subjects with advanced, metastatic disease will be included in this trail.


Condition Intervention Phase
Soft Tissue Sarcoma
 Drug: Vorinostat
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma

Resource links provided by NLM:

Drug Information available for: Vorinostat
U.S. FDA Resources

Further study details as provided by University of Heidelberg:

Primary Outcome Measures:
  • Evaluation of the efficacy of vorinostat on the basis of progression free survival (PFS) up to 1 year after first administration of the IMP. [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of the efficacy of vorinostat on the basis of overall survival up to 1 year after first administration of the IMP. Investigation on pharmacokinetics und pharmacodynamics of vorinostat. Evaluation of safety and tolerability of vorinostat. [ Time Frame: Up to 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: May 2010
Arms Assigned Interventions
Experimental: Vorinostat
Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
 Drug: Vorinostat
Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.

Detailed Description:

The treatment with vorinostat will be administered daily over 28 days. This period will be referred to as a therapy cycle. Two consecutive therapy cycles will be separated by a 7-days therapy break. In case of a good response and no relevant side effects, the treatment with vorinostat can be continued for up to 1 year after begin of the treatment. If any relevant side effects or intolerability occur, the dose and/or schedule of administration will be modified according to the pre-defined criteria.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with verified, metastatic soft tissue sarcoma of the following histologies:

    • undifferentiated highgrade pleomorphic sarcoma/pleomorphic malignant fibrous histiocytoma,
    • undifferentiated pleomorphic sarcoma with grand cells/grand cell fibrotic histiocytoma,
    • undifferentiated pleomorphic sarcoma with prominent inflammation/inflamed MFH,
    • myxofibrosarcoma,
    • liposarcoma,
    • synovial sarcoma,
    • rhabdomyosarcoma (pleomorph, alveolar und embryonal),
    • leiomyosarcoma,
    • adult fibrosarcoma,
    • angiosarcoma,
    • malignant hemangiopericytoma/ malignant solitaire fibrous tumor,
    • malignant peripheral neurilemma tumor,
    • extraskeletal mesenchymal chondrosarcoma,
    • extraskeletal myxoid chondrosarcoma,
    • undifferentiated sarcoma of non other specified (NOS) type.
  2. Verified relapse or disease progression at study inclusion, i.e. therapeutic failure of the first line therapy with anthracyclines,
  3. Measurable disease according to the RECIST criteria,
  4. Previous systemic therapy of advanced and/or metastatic disease,
  5. An interval of at least 4 weeks since the last surgery, chemotherapy or radiation,
  6. Age over 18,

  7. Following laboratory findings:

    • ANC ≥ 1.0 x 10³/mm³,
    • platelets ≥ 100.000/mm³,
    • hemoglobin ≥ 9 g/dl,
    • creatinin < 1.5 x ULN (upper limit of normal),
    • AST and ALT < 2.5 x ULN,
    • total bilirubin < 1.5 x ULN,
  8. Life expectancy of at least 12 weeks,
  9. Negative pregnancy test,
  10. Consent for an effective contraception during and up to 6 month after the study completion.
  11. Written informed consent,
  12. Ability to understand the goal and the consequences of this trial.

Exclusion Criteria:

  1. Proof of the following histologies:

    • gastrointestinal stromal tumor (GIST),
    • malignant mesothelioma,
    • neuroblastoma,
    • osteosarcoma,
    • Ewing's sarcoma/PNET,
  2. Concurrent radio- or chemotherapy,
  3. Participation in another interventional trial within 4 weeks prior to the inclusion,
  4. Previous therapy with another HDAC-inhibitor (e.g. depsipeptide, MS-275, LAQ-824, PXD-101 und valproic acid). Patients, who underwent a therapy with valproic acid for treatment of seizures, can be included after a wash-out period of at least 30 days,
  5. Symptomatic brain metastases, that have not been treated by radiotherapy. The interval between the last radiation and the study inclusion must not be shorter than 30 days,
  6. Previous malignant disease (except for a non-melanoma of the skin and a carcinoma in situ of uterus), unless in complete remission and after the last therapy for at least 5 years,
  7. Ejection fraction < 40 %,
  8. Nursing,
  9. Known allergy against the IMP or drugs with similar chemical structure or additives,
  10. Active hepatitis B and/or C and HIV-infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00918489

Contacts
Contact: Gerlinde Egerer, MD +49 06221 56 ext 8002 Gerlinde.Egerer@med.uni-heidelberg.de
Contact: Thomas Schmitt, MD +49 06221 56 ext 39067 Thomas.Schmitt@med.uni-heidelberg.de

Locations
Germany
Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen Recruiting
Tübingen, Baden-Württemberg, Germany, D-72076
Contact: Jörg Hartmann, MD     +49 07071 / 29 ext 82127     Joerg.Hartmann@med.uni-tuebingen.de    
Principal Investigator: Jörg Hartmann, MD            
Department of Hematology, Hemostaseology, Oncology and Stemm Cell Transplantation, Medical School Hannover Recruiting
Hannover, Niedersachen, Germany, D-30625
Contact: Viktor Grünwald, MD     +49 0511 532 ext 0     Gruenwald.Viktor@mh-hannover.de    
Principal Investigator: Viktor Grünwald, MD            
Department of Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf Recruiting
Düsseldorf, Nordrhein-Westfalen, Germany, D-40479
Contact: Jochen Schütte, MD     +49 0211 4400 ext 2501     Jochen.Schuette@marien-hospital.de    
Principal Investigator: Jochen Schütte, MD            
Comprehensive Cancer Center North, University Hospital Kiel Recruiting
Kiel, Germany, 24105
Contact: Joerg T Hartmann, MD     +49 0431 597 ext 2484     joerg.hartmann@uk-sh.de    
Principal Investigator: Joerg T Hartmann, MD            
Sarcoma Center Mannheim, University Hospital Mannheim Recruiting
Mannheim, Germany, 68167
Contact: Peter Hohenberger, MD     +49 0621/383-24 ext 47     peter.hohenberger@umm.de    
Principal Investigator: Peter Hohenberger, MD            
Center for Soft Tissue Sarcoma, University Hospital Tübingen Recruiting
Tübingen, Germany, 72074
Contact: Frank Mayer, MD     +49 07071 2980 ext 65     Frank.Mayer@med.uni-tuebingen.de    
Principal Investigator: Frank Mayer, MD            
Comprehensive Cancer Center Ulm (CCCU) Recruiting
Ulm, Germany, 89081
Contact: Regine Mayer-Steinacker, MD     +49 0731 500 560 ext 56     regine.mayer-steinacker@uniklinik-ulm.de    
Principal Investigator: Regine Mayer-Steinacker, MD            
Sponsors and Collaborators
University of Heidelberg
Merck
Investigators
Study Director: Gerlinde Egerer, MD Department of Internal Medicine V, Universtity Hospital Heidelberg
  More Information

No publications provided

Responsible Party: Coordinating investigator: PD Dr. Gerlinde Egerer, Department of Internal Medicine V, University Hospital Heidelberg
ClinicalTrials.gov Identifier: NCT00918489     History of Changes
Other Study ID Numbers: SAHA-I
Study First Received: June 10, 2009
Last Updated: February 14, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Heidelberg:
soft tissue sarcoma
metastatic
vorinostat

Additional relevant MeSH terms:
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Vorinostat
Histone Deacetylase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013